NASDAQ:PHVS Pharvaris Q2 2025 Earnings Report $29.47 -0.41 (-1.37%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$31.62 +2.16 (+7.31%) As of 05/27/2026 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pharvaris EPS ResultsActual EPS-$0.94Consensus EPS -$0.87Beat/MissMissed by -$0.07One Year Ago EPSN/APharvaris Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APharvaris Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time6:00PM ETUpcoming EarningsPharvaris' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Pharvaris Earnings HeadlinesPharvaris (NASDAQ:PHVS) CFO David Nassif Sells 10,000 Shares of StockMay 27 at 5:58 AM | americanbankingnews.comPharvaris (NASDAQ:PHVS) Director Viviane Monges Sells 9,667 Shares of StockMay 27 at 5:58 AM | americanbankingnews.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window. | Behind the Markets (Ad)Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 5,501 Shares of StockMay 27 at 4:58 AM | americanbankingnews.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 27 at 4:25 AM | americanbankingnews.comPharvaris (NASDAQ:PHVS) Director Sells $293,200.00 in StockMay 25 at 5:14 AM | americanbankingnews.comSee More Pharvaris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email. Email Address About PharvarisPharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes. The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies. Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization. Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.View Pharvaris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Abercrombie Rallies as Strong Q1 Earnings Extend Winning StreakZscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityRecord Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy?Micron’s $1 Trillion Memory Melt-UpKeysight: The AI and Defense Stock Seeing Big Price Target BoostsAutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Upcoming Earnings Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026)Dell Technologies (5/28/2026)Royal Bank Of Canada (5/28/2026)Toronto Dominion Bank (5/28/2026)Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
